77779-50-1

Usage

Uses

Used in Pharmaceutical Industry:
2,5-dihydro-2-(4-methoxyphenyl)-3H-pyrazolo(4,3-c)quinolin-3-one is used as a potential therapeutic agent for various conditions due to its pharmacological properties. The presence of the methoxy group and the pyrazoloquinolinone structure may contribute to its efficacy in treating specific diseases.
Used in Medicinal Chemistry Research:
2,5-dihydro-2-(4-methoxyphenyl)-3H-pyrazolo(4,3-c)quinolin-3-one is utilized in the field of medicinal chemistry as a subject of study for its potential anti-inflammatory, antitumor, and antiviral activities. Its structure and functional groups are of interest to researchers seeking to develop new drugs with improved efficacy and safety profiles.
Further research is necessary to fully elucidate the biological effects and applications of 2,5-dihydro-2-(4-methoxyphenyl)-3H-pyrazolo(4,3-c)quinolin-3-one, including its mechanism of action and optimal therapeutic uses.

InChI:InChI=1/C17H13N3O2/c1-22-12-8-6-11(7-9-12)20-17(21)14-10-18-15-5-3-2-4-13(15)16(14)19-20/h2-10,19H,1H3

Upstream product

• 13720-94-0 ethyl 4-chloroquinoline-3-carboxylate 
• 3471-32-7 4-Methoxyphenylhydrazine 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 52980-28-6 ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 62-53-3 aniline 
• 26892-90-0 ethyl 4-hydroxy-3-quinolinecarboxylate 

Downstream Products

• 77779-51-2 CGS 11361 

Relevant academic research and scientific papers

Synthesis and preliminary structure-activity relationship study of 2-aryl-2H-pyrazolo[4,3-c]quinolin-3-ones as potential checkpoint kinase 1 (Chk1) inhibitors

The serine-threonine checkpoint kinase 1 (Chk1) plays a critical role in the cell cycle arrest in response to DNA damage. In the last decade, Chk1 inhibitors have emerged as a novel therapeutic strategy to potentiate the anti-tumour efficacy of cytotoxic chemotherapeutic agents. In the search for new Chk1 inhibitors, a congeneric series of 2-aryl-2 H-pyrazolo[4,3-c]quinolin-3-one (PQ) was evaluated by in-vitro and in-silico approaches for the first time. A total of 30 PQ structures were synthesised in good to excellent yields using conventional or microwave heating, highlighting that 14 of them are new chemical entities. Noteworthy, in this preliminary study two compounds 4e2 and 4h2 have shown a modest but significant reduction in the basal activity of the Chk1 kinase. Starting from these preliminary results, we have designed the second generation of analogous in this class and further studies are in progress in our laboratories.

THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES

The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and modulating GABAA, and use of the compound of formula I for the treatment

High affinity central benzodiazepine receptor ligands. Part 2: Quantitative structure-activity relationships and comparative molecular field analysis of pyrazolo[4,3-c]quinolin-3-ones

A large series of 2-aryl(heteroaryl)-2,5-dihydropyrazolo[4,3-c]quinolin-3(3H)-ones (PQ, 106 compounds), carrying appropriate substituents at the quinoline and N2-phenyl rings, were designed, prepared and tested as central benzodiazepine recepto

Structure-activity relationship studies at the benzodiazepine receptor (BZR): A comparison of the substituent effects of pyrazoloquinolinone analogs

The synthesis of a series of 2-phenylpyrazolo[4,3-c]quinolin-3-one derivatives and their in vitro biological evaluation as ligands for the benzodiazepine receptor are described. The in vitro activities, as determined by an analysis of GABA shift ratios, a